Insights: Letrozole and Early Miscarriage Management

Written by Kenya Lyons, MD The administration of mifepristone followed by misoprostol is a highly effective regimen for the management of first-trimester miscarriage and medication abortion.1 However, even prior to the onset of legal challenges to mifepristone, including FDA v. Alliance for Hippocratic Medicine, the search for alternative therapies existed. This has been driven by…

Contraceptive Pearl: Ulipristal Acetate Myths

Written by Veronica Flake, MD Ulipristal Acetate (ella, UPA) is an effective emergency contraception (EC) method, given as a one-time, 30-mg dose, which can be used for up to 120 hours after unprotected sexual intercourse to prevent pregnancy. UPA is a selective progesterone receptor modulator with antagonistic and partial agonistic effects that prevents or delays…

2024-05- NY Expand Access to GAHC

Comparing Tubal Sterilization with Long-Acting Reversible Contraceptives

This resource from the University of California San Francisco compares tubal sterilization with long-acting reversible contraceptive (LARC) methods like the IUD and Implant.

Insights: Part Two: Misoprostol-only Medication Abortion

Written by Brandy Bautista This article was published in April 2024, before the Supreme Court released its ruling in Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration on June 13th. In its ruling, the Supreme Court unanimously rejected the challenge to mifepristone access. While we celebrate this decision, we know this will not…

Fellowship Frequently Asked Question

Frequently Asked Questions: Do you accept applicants with no experience or a lot of experience? We accept applicants with previous experience as well as those without any.  We do not require applicants to have prior procedural abortion training. We have and do accept people with nearly no procedural training experience. In our application review, we…

Know Your State’s Abortion Laws Guides for Medical Providers

Since the Supreme Court overturned Roe v. Wade, medical providers in states where abortion is banned or severely restricted have struggled to understand how state laws apply to them and their patients. This resource from the Abortion Defense Network aims to provide clarification, where possible, of what conduct is permitted in the states where the…

Contraceptive Pearl: The Latest Updates on the Over-the-Counter Contraceptive Pill

By Joi C. Spaulding MD, MS Opill, a daily progestin-only birth control pill (POP), was first approved for over-the-counter (OTC) use by the United States Food and Drug Administration (FDA) on July 13, 2023. As of March 2024, the pill is now available to people of all ages to purchase at retailers online and in…

Your Birth Control Choices Poster

This poster compares birth control choices based on efficacy, cost, side effects, and other patient-focused factors.

Insights: Prenatal Drug Testing and Reporting: What does the Child Abuse Prevention and Treatment Act (CAPTA) actually require of healthcare providers?

Written by Rebecca Wang, JD, Senior Legal Support Counsel and Lauren Paulk, JD, Senior Research Counsel Mandatory reporting is not an evidence-based practice. Neither is punishing providers for a failure to report. Still, healthcare provider reports to Child Protective Services of infants have increased substantially over the last decade.¹ This is despite only two states…